Nephrotic Syndrome

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical judgment, patient-specific factors, and current local guidelines must always be considered. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care.

Overview

• Definition: Nephrotic syndrome is a clinical constellation characterized by massive proteinuria (>3.5 grams per 1.73 m² body surface area per 24 hours in adults, or >40 mg/m²/hour in children, or urine protein-to-creatinine ratio >3.5 mg/mg or 3500 mg/g), hypoalbuminemia (<3.0 g/dL), peripheral edema, and hyperlipidemia. It results from increased glomerular permeability, leading to excessive protein loss in the urine.
• Epidemiology:
  • Incidence: Approximately 3-4 cases per 100,000 adults per year.
  • Children: More common in children, with an incidence of 2-7 cases per 100,000 children per year. Minimal Change Disease (MCD) is the most common cause in children (80-90%), while Focal Segmental Glomerulosclerosis (FSGS) and Membranous Nephropathy (MN) are more prevalent in adults.
  • Gender: Varies by etiology. MCD is slightly more common in boys.
  • Ethnicity: FSGS has a higher incidence and progression rate in African Americans, often linked to APOL1 gene variants.
• Classification:
  • Primary (Idiopathic) Nephrotic Syndrome: Glomerular diseases where nephrotic syndrome is the primary manifestation, without an identifiable systemic cause.
    • Minimal Change Disease (MCD)
    • Focal Segmental Glomerulosclerosis (FSGS)
    • Membranous Nephropathy (MN)
    • Membranoproliferative Glomerulonephritis (MPGN) - less common, often secondary
    • IgA Nephropathy (IgAN) - can present with nephrotic-range proteinuria
  • Secondary Nephrotic Syndrome: Nephrotic syndrome occurring as a manifestation of a systemic disease or other identifiable cause.
    • Systemic Diseases:
      • Diabetic Nephropathy (most common cause of ESRD in developed countries)
      • Systemic Lupus Erythematosus (Lupus Nephritis)
      • Amyloidosis
      • Vasculitis
      • Sickle Cell Anemia
      • HIV-associated Nephropathy (HIVAN, a form of collapsing FSGS)
      • Syphilis, Hepatitis B/C
    • Drugs: NSAIDs, Gold, Penicillamine, Heroin, Lithium, Pamidronate.
    • Malignancy: Lymphoma, leukemia, solid tumors (paraneoplastic).
    • Genetic Disorders: Alport syndrome, Nail-Patella syndrome, genetic forms of FSGS.

Pathophysiology

• Mechanism: The fundamental defect is an increased permeability of the glomerular capillary wall to plasma proteins, primarily albumin. This typically results from injury to the podocytes (specialized epithelial cells lining the outer aspect of the glomerular basement membrane) and/or defects in the glomerular basement membrane (GBM).
  • Podocyte Injury: In MCD, there is diffuse effacement of podocyte foot processes. In FSGS, there is segmental podocyte detachment and sclerosis. In MN, immune complex deposition leads to podocyte damage.
  • Charge Selectivity Loss: The anionic charges of the GBM and podocytes normally repel negatively charged albumin. Damage to these structures can lead to a loss of charge selectivity, allowing albumin to pass.
  • Size Selectivity Loss: Increased pore size in the glomerular filter can also contribute, though this is less dominant than charge barrier disruption for albumin.
  • Consequences of Proteinuria:
    • Hypoalbuminemia: Due to urinary albumin loss exceeding hepatic synthesis capacity. This reduces plasma oncotic pressure.
    • Edema: Decreased plasma oncotic pressure leads to fluid shift from the intravascular space into the interstitial space. Activation of the renin-angiotensin-aldosterone system (RAAS) and antidiuretic hormone (ADH) secretion contribute by increasing renal sodium and water reabsorption (underfill vs. overflow hypothesis).
    • Hyperlipidemia: Mechanisms include increased hepatic synthesis of lipoproteins (in response to hypoalbuminemia and decreased oncotic pressure) and decreased catabolism of lipoproteins (due to reduced lipoprotein lipase activity).
    • Hypercoagulability: Due to urinary loss of anticoagulant proteins (e.g., antithrombin III), increased synthesis of procoagulant factors (e.g., fibrinogen, factors V, VII, VIII, X), platelet hyperaggregability, and increased blood viscosity from hyperlipidemia.
    • Increased Infection Risk: Due to urinary loss of immunoglobulins (IgG) and complement factors (factor B), impaired cellular immunity.
• Risk Factors:
  • Underlying Systemic Diseases: Diabetes mellitus, systemic lupus erythematosus, amyloidosis, certain infections (HIV, Hepatitis B/C), certain cancers.
  • Medications: NSAIDs, gold, penicillamine, lithium, heroin, pamidronate.
  • Genetic Predisposition: APOL1 gene variants (especially for FSGS in individuals of African ancestry), NPHS1, NPHS2, WT1, TRPC6 genes (for congenital/familial forms).
  • Obesity: Associated with increased risk of FSGS.
  • Environmental Toxins: Some chemicals.
• Protective Factors:
  • Good Control of Underlying Systemic Diseases: Strict glycemic control in diabetes, effective disease management in lupus.
  • Avoiding Nephrotoxic Drugs: Where possible.
  • Healthy Lifestyle: Maintaining a healthy weight, balanced diet, regular exercise can generally reduce risk of kidney disease, but specific protection against primary nephrotic syndrome is not well-defined.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Edema: The most prominent symptom. Typically soft, pitting, symmetric, and dependent.
    • Periorbital edema (especially in the morning, more prominent in children).
    • Lower extremity edema (ankles, feet).
    • Scrotal/labial edema.
    • Anasarca (generalized massive edema, including ascites, pleural effusions, pericardial effusions) in severe cases.
  • Foamy Urine: Due to high protein content.
  • Weight Gain: Due to fluid retention.
  • Fatigue/Malaise: Non-specific, can be due to underlying disease, anemia, or general ill health.
• Early Signs:
  • Subtle swelling around the eyes or ankles.
  • Mild increase in weight.
  • Foamy urine.
• Advanced Signs:
  • Severe anasarca, compromising mobility and organ function.
  • Dyspnea (due to pleural effusions or ascites elevating the diaphragm).
  • Abdominal distension and discomfort (ascites).
  • Symptoms of complications:
    • Abdominal pain (spontaneous bacterial peritonitis, renal vein thrombosis).
    • Chest pain, dyspnea, hemoptysis (pulmonary embolism).
    • Fever, chills (infection).
    • Symptoms of acute kidney injury (oliguria, worsening fatigue).
    • Xanthomas/Xanthelasmas (cutaneous manifestations of severe hyperlipidemia).
• Atypical Presentations:
  • May present primarily with symptoms of an underlying systemic disease (e.g., rash and joint pain in SLE).
  • May be discovered incidentally on routine urine testing (proteinuria).
  • Acute kidney injury may precede or coincide with overt nephrotic syndrome symptoms, particularly in collapsing FSGS or rapidly progressive glomerulonephritis.

Physical Examination

• Inspection:
  • Edema: Diffuse pitting edema, most prominent in dependent areas (ankles, sacrum) and around the eyes.
  • Anasarca: Generalized body swelling, including facial puffiness.
  • Ascites: Abdominal distension.
  • Pleural Effusions: Reduced chest wall expansion, signs of respiratory distress.
  • Skin Changes: Striae (from rapid skin stretching), pallor (anemia), xanthelasmas/xanthomas (hyperlipidemia).
  • Signs of Underlying Disease: Malar rash (SLE), purpura (vasculitis), joint swelling (SLE).
• Palpation:
  • Pitting Edema: Firm pressure leaves an indentation.
  • Abdominal Palpation: May reveal fluid wave (ascites), hepatomegaly (due to fluid congestion or fatty liver).
  • Lymphadenopathy: May suggest underlying malignancy or systemic disease.
• Special Tests:
  • Fluid Wave and Shifting Dullness: To confirm ascites.
  • Chest Auscultation: Diminished breath sounds at lung bases (pleural effusions).
  • Cardiac Auscultation: Pericardial rub (pericardial effusion), signs of fluid overload.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Duration of Edema: When did it start? Where did it begin? Is it worse in the mornings (periorbital) or evenings (leg swelling)?
  • Urine Characteristics: Is urine foamy? Any change in urine volume? Color?
  • Weight Changes: Recent weight gain?
  • Symptoms of Complications: Abdominal pain, chest pain, shortness of breath, fever, chills, calf pain/swelling (DVT).
  • Past Medical History: Diabetes, lupus, hepatitis, HIV, cancer, kidney disease in family.
  • Medication History: NSAIDs, gold, lithium, other nephrotoxic drugs.
  • Social History: IV drug use (HIV, Hep C), occupational exposures.
  • Family History: Kidney disease, autoimmune disorders.
• Red Flags:
  • Rapid onset of severe edema/anasarca: Suggests aggressive disease or acute complication.
  • Signs of DVT/PE: Unilateral leg swelling, acute dyspnea, chest pain.
  • Acute Abdominal Pain/Fever: Suggests spontaneous bacterial peritonitis.
  • Acute Kidney Injury (AKI): Rapid decline in urine output and/or rising creatinine.
  • Hematuria: May indicate proliferative glomerulonephritis or vasculitis.
  • Rash, Arthralgias, Oral Ulcers: Suggests systemic autoimmune disease (e.g., SLE).

Laboratory Tests

• First-Line:
  • Urinalysis: Dipstick for protein (3+ or 4+), microscopy for cellular casts (red cell casts suggest nephritis, oval fat bodies/fatty casts are pathognomonic but not always present).
  • Quantification of Proteinuria:
    • 24-hour urine collection for protein: Gold standard. Nephrotic range defined as >3.5 g/24 hours in adults, or >40 mg/m²/hour in children.
    • Spot urine protein-to-creatinine ratio (UPCR): Convenient, correlates well with 24-hour collection, especially for high levels of proteinuria. A UPCR >3.5 mg/mg (or 3500 mg/g) is indicative of nephrotic-range proteinuria.
  • Serum Albumin: Typically <3.0 g/dL.
  • Serum Lipids: Elevated total cholesterol (>200 mg/dL), LDL cholesterol (>100 mg/dL), triglycerides (>150 mg/dL).
  • Renal Function Tests: Serum creatinine, blood urea nitrogen (BUN), estimated Glomerular Filtration Rate (eGFR).
  • Electrolytes: Sodium, potassium, chloride, bicarbonate.
• Confirmatory (for diagnosis and etiology):
  • Renal Biopsy: Essential for determining the underlying cause of primary nephrotic syndrome and guiding specific therapy, especially in adults. Consider in children who do not respond to steroids or have atypical features. Contraindications: uncontrolled severe hypertension, solitary kidney (relative), bleeding diathesis.
• Monitoring (to identify secondary causes and complications):
  • Complete Blood Count (CBC): To check for anemia (dilutional, iron deficiency, chronic disease) and leukocytosis (infection).
  • C-reactive protein (CRP) / Erythrocyte Sedimentation Rate (ESR): Markers of inflammation, may be elevated in infections or systemic diseases.
  • Blood Glucose/HbA1c: To screen for diabetes.
  • Immunologic Tests:
    • Antinuclear Antibodies (ANA), Anti-dsDNA: For Systemic Lupus Erythematosus.
    • Complement levels (C3, C4): Reduced in some forms of lupus nephritis, MPGN, post-infectious GN.
    • Antiphospholipid Antibodies: Lupus anticoagulant, anti-cardiolipin antibodies, anti-beta-2-glycoprotein I antibodies (for hypercoagulability, APS).
    • Anti-PLA2R antibodies: Highly specific for primary Membranous Nephropathy.
    • Anti-neutrophil cytoplasmic antibodies (ANCA): For ANCA-associated vasculitis.
    • Serum and Urine Protein Electrophoresis (SPEP/UPEP) with Immunofixation: To screen for monoclonal gammopathy (e.g., amyloidosis, light chain deposition disease).
  • Viral Serologies: Hepatitis B, Hepatitis C, HIV.
  • Thyroid Function Tests: Hypothyroidism can cause hyperlipidemia.
  • D-dimer: For suspicion of thrombotic complications.

Imaging

• Recommended:
  • Renal Ultrasound: To assess kidney size, echogenicity (corticomedullary differentiation), and rule out obstruction. Small, echogenic kidneys suggest chronic kidney disease. Hydronephrosis indicates obstruction.
  • Chest X-ray: To evaluate for pleural effusions or pulmonary edema.
• Advanced:
  • Doppler Ultrasound of Renal Veins: If renal vein thrombosis is suspected (e.g., sudden worsening of renal function, flank pain, gross hematuria).
  • CT Angiography/MR Venography: More definitive for diagnosing renal vein thrombosis or other vascular complications.
  • Echocardiogram: To assess for pericardial effusion, cardiac function, or features of amyloidosis.
  • CT Scan of Abdomen/Pelvis: To assess for ascites, organomegaly, or rule out malignancy as a secondary cause.

Management

Management involves treating the underlying cause (if secondary), reducing proteinuria, managing symptoms, and preventing complications.

Acute Management

• Immediate (within hours-days of severe presentation):
  • Fluid and Electrolyte Management:
    • Diuretics: Loop diuretics (e.g., Furosemide) are mainstay for edema. Start with low dose (e.g., Furosemide 20-40 mg IV/PO) and titrate up. Higher doses (e.g., 80-160 mg BID) may be needed due to reduced effect in hypoalbuminemia (less drug delivered to tubular lumen). May combine with thiazide diuretics (e.g., Metolazone 2.5-10 mg PO 30 mins before loop diuretic) for synergistic effect in refractory edema.
    • Albumin Infusion: For severe symptomatic edema, especially with hypovolemia/hypotension (rare but can occur due to profound fluid shift) or resistance to diuretics. Typically, 25% albumin, 50-100g, infused over 2-4 hours, often followed by furosemide to mobilize fluid from the intravascular space. Caution: Can worsen fluid overload if not followed by diuretics.
  • Blood Pressure Management: Control hypertension, especially if AKI is present. ACE inhibitors/ARBs are preferred due to antiproteinuric effects.
  • Anticoagulation Prophylaxis: Consider if high risk for thrombosis (e.g., albumin <2.0-2.5 g/dL, severe hyperlipidemia, active infection, immobilization). LMWH (e.g., Enoxaparin 40 mg SC daily) is common.
• Stabilization (early management priorities):
  • Address Proteinuria: Start therapy for underlying glomerular disease if identified (e.g., corticosteroids for MCD, immunosuppression for FSGS/MN).
  • Nutritional Support: Ensure adequate protein intake (but avoid excessive amounts), sodium restriction (2-4 g/day) for edema.
  • Infection Surveillance: Monitor for signs of infection; administer appropriate antibiotics if present. Pneumococcal vaccine is recommended.
• Emergency (crisis management):
  • Severe Anasarca with Respiratory Distress: Aggressive diuresis, potentially with albumin. Consider thoracentesis/paracentesis if effusions/ascites are compromising respiration.
  • Thrombosis (e.g., DVT, PE, Renal Vein Thrombosis): Immediate therapeutic anticoagulation.
  • Spontaneous Bacterial Peritonitis: Empirical broad-spectrum antibiotics (e.g., third-generation cephalosporins), paracentesis for diagnosis.
  • Acute Kidney Injury: Address reversible causes (hypovolemia, nephrotoxins), adjust medications, consider dialysis if severe.

Chronic Management

• Pharmacological:
  • Immunosuppression: Specific to the underlying histological diagnosis (determined by renal biopsy).
    • Minimal Change Disease (MCD):
      • First-line: Corticosteroids (e.g., Prednisone 1 mg/kg/day or 2 mg/kg every other day, max 60-80 mg/day, for 4-16 weeks, then taper).
      • Steroid-dependent/frequent relapses: Calcineurin inhibitors (Cyclosporine, Tacrolimus), Mycophenolate Mofetil (MMF), Rituximab, Cyclophosphamide.
    • Focal Segmental Glomerulosclerosis (FSGS):
      • Primary FSGS: Corticosteroids (similar to MCD but often longer duration, 3-6 months), Calcineurin inhibitors (Cyclosporine 3-5 mg/kg/day or Tacrolimus 0.05-0.1 mg/kg/day, aiming for trough levels), MMF. Rituximab is an emerging option.
      • Secondary FSGS: Treat underlying cause (e.g., weight loss for obesity-related FSGS). Immunosuppression generally not indicated unless primary component suspected.
    • Membranous Nephropathy (MN):
      • High-risk patients (persistent high proteinuria, declining GFR): Immunosuppression based on KDIGO guidelines (e.g., combination of corticosteroids with cyclophosphamide or calcineurin inhibitors, or rituximab).
      • Low-to-moderate risk: Observation, ACEi/ARBs, statins.
    • Lupus Nephritis: Treatment varies by class, often corticosteroids plus MMF or cyclophosphamide.
  • Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors:
    • ACE Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs): (e.g., Enalapril 5-20 mg/day, Losartan 25-100 mg/day). First-line for proteinuria reduction, renoprotection, and blood pressure control. Start low and titrate based on BP and potassium. Monitor creatinine.
  • Statins: (e.g., Atorvastatin 10-80 mg/day, Rosuvastatin 5-40 mg/day). For hyperlipidemia, recommended for all nephrotic patients, regardless of baseline lipid levels, due to high cardiovascular risk.
  • Anticoagulation: Prophylactic (LMWH or warfarin targeting INR 2-3) if severe hypoalbuminemia (serum albumin <2.0-2.5 g/dL) and other risk factors for thrombosis persist. Therapeutic anticoagulation for diagnosed thrombosis.
  • Diuretics: Continue as needed for edema control.
• Non-pharmacological:
  • Sodium Restriction: <2 grams/day to reduce edema.
  • Fluid Restriction: Usually not necessary unless severe hyponatremia or severe edema despite diuretics.
  • Dietary Protein: Avoid excessive intake. Moderate protein intake (0.8-1.0 g/kg/day) is generally recommended.
  • Lipid Management: Low-fat diet in conjunction with statins.
  • Blood Pressure Control: Target <130/80 mmHg.
  • Vaccinations: Pneumococcal vaccine (PCV13 and PPSV23), annual influenza, Hepatitis B vaccine (if indicated) due to increased infection risk and immunosuppression.
• Monitoring:
  • Regularly: Blood pressure, weight, edema.
  • Laboratory:
    • Urine protein (UPCR or 24h): To monitor response to therapy.
    • Serum albumin: To monitor nutritional status and disease activity.
    • Lipid panel: To assess efficacy of statins.
    • Renal function (Cr, eGFR, electrolytes): To monitor kidney function and medication side effects.
    • Drug-specific monitoring: e.g., Cyclosporine/Tacrolimus trough levels, CBC for cyclophosphamide/MMF, liver function tests.
  • Frequency: Initially weekly or bi-weekly, then monthly to quarterly depending on disease activity and medication.

Treatment Algorithms

• First-Line (based on biopsy findings):
  • Minimal Change Disease (MCD):
    • Adults & Children: Oral corticosteroids (Prednisone 1 mg/kg/day or 2 mg/kg every other day). Duration typically 4-16 weeks for adults, 4-6 weeks for children, followed by a slow taper.
  • Focal Segmental Glomerulosclerosis (FSGS):
    • Primary FSGS: Corticosteroids (longer courses, 3-6 months) or Calcineurin Inhibitors (Cyclosporine or Tacrolimus).
    • Secondary FSGS: Treat underlying cause; usually no immunosuppression.
  • Membranous Nephropathy (MN):
    • Low Risk (mild proteinuria, stable GFR): Conservative management with ACEi/ARBs, statins, observation.
    • Moderate/High Risk (persistent nephrotic syndrome, declining GFR, high PLA2R titers): Immunosuppression (e.g., modified Ponticelli regimen: corticosteroids alternating with cyclophosphamide, or calcineurin inhibitors, or Rituximab).
• Second-Line (for steroid-resistant or steroid-dependent cases):
  • MCD: Calcineurin inhibitors (Cyclosporine, Tacrolimus), Mycophenolate Mofetil, Rituximab, Cyclophosphamide (rarely).
  • FSGS: Calcineurin inhibitors, MMF, Rituximab.
  • MN: Consider alternative immunosuppressants (e.g., Cyclosporine if previously on Rituximab, or vice-versa), or combination therapy.
• Refractory Cases:
  • Consult Nephrologist: Re-biopsy may be considered if initial diagnosis is uncertain or disease course is atypical.
  • Combination Therapies: Use of multiple immunosuppressants (e.g., calcineurin inhibitor + MMF, though evidence is limited).
  • Novel Therapies: Consider participation in clinical trials. Emerging drugs targeting specific pathways (e.g., anti-APRIL for IgAN, SGLT2 inhibitors).
  • Supportive Care: Aggressive management of edema, dyslipidemia, and thrombotic risk, optimization of RAAS blockade. Dialysis for ESRD.

Complications

• Common:
  • Edema: Leading to skin breakdown, cellulitis, impaired mobility, dyspnea.
  • Hyperlipidemia: Significantly increases cardiovascular disease risk (atherosclerosis).
  • Hypercoagulability: Increased risk of venous and arterial thromboembolism.
  • Infections: Due to loss of immunoglobulins (IgG) and complement factors, impaired cellular immunity, especially bacterial peritonitis, cellulitis, pneumonia, sepsis.
  • Acute Kidney Injury (AKI): Can be due to severe hypovolemia, ATN, superimposed glomerulonephritis, renal vein thrombosis, or medication side effects.
  • Hypovolemia/Orthostatic Hypotension: Paradoxically, despite generalized edema, severe intravascular volume depletion can occur due to fluid shift.
• Serious:
  • Venous Thromboembolism (VTE):
    • Deep Vein Thrombosis (DVT): Common in lower extremities.
    • Pulmonary Embolism (PE): Life-threatening.
    • Renal Vein Thrombosis (RVT): Can cause acute flank pain, hematuria, acute kidney injury. Most common in Membranous Nephropathy.
  • Spontaneous Bacterial Peritonitis (SBP): Fever, abdominal pain, tenderness. High mortality if untreated.
  • Severe Sepsis/Septic Shock: From any infection.
  • Cardiovascular Disease: Accelerated atherosclerosis due to chronic hyperlipidemia and inflammation.
  • Acute Adrenal Insufficiency: If corticosteroids are abruptly withdrawn after prolonged use.
  • Progression to End-Stage Renal Disease (ESRD): Especially with FSGS, rapidly progressive MN, or poorly controlled secondary causes.
• Long-term:
  • Chronic Kidney Disease (CKD): Progressive loss of kidney function.
  • ESRD: Requiring dialysis or kidney transplantation.
  • Malnutrition: Due to anorexia, protein loss, impaired absorption.
  • Bone Disease: From vitamin D loss, chronic corticosteroid use, and CKD-MBD.
  • Anemia: Due to chronic disease, iron deficiency (transferrin loss), or dilutional effects.
  • Growth Retardation in Children: Due to malnutrition, chronic illness, and corticosteroids.

Prognosis

• Factors:
  • Underlying Histology:
    • MCD: Generally excellent prognosis with steroid responsiveness. Relapses are common but often respond to treatment. Progression to ESRD is rare.
    • FSGS: Variable, but often less favorable. Up to 50% may progress to ESRD within 5-10 years, especially in steroid-resistant cases or certain genetic variants.
    • MN: Variable course. About 30% undergo spontaneous remission, 30% have persistent proteinuria, and 30% progress to ESRD over 10 years. Anti-PLA2R antibody levels can predict prognosis and response to therapy.
    • Diabetic Nephropathy: Slowly progressive, but majority will eventually develop CKD/ESRD without intensive management.
  • Response to Therapy: Complete or partial remission of proteinuria is the strongest predictor of favorable long-term renal survival, regardless of the underlying cause.
  • Degree of Proteinuria: Higher baseline proteinuria and failure to achieve remission are associated with worse outcomes.
  • Initial Renal Function: Presence of AKI at presentation or persistently elevated creatinine indicates poorer prognosis.
  • Age: Children with MCD generally have better renal outcomes than adults with FSGS or MN. Elderly patients often have more comorbidities and are less tolerant of aggressive immunosuppression.
  • Complications: Recurrent infections, thrombotic events, or severe cardiovascular disease worsen outcomes.
• Survival:
  • Overall Mortality: Varies significantly by cause and age. Mortality rates are higher than the general population, mainly due to cardiovascular events, infections, and progression to ESRD.
  • Renal Survival: Highly dependent on the specific underlying glomerular disease and response to treatment.
• Quality of Life:
  • Can be significantly impaired by chronic edema, fatigue, frequent hospitalizations, medication side effects, and the psychological burden of chronic illness.
  • Children may experience stunted growth, impaired social development, and educational disruption.

Prevention

• Primary (Preventing Initial Occurrence): Not directly preventable for most primary forms of nephrotic syndrome.
  • Good Management of Systemic Diseases: Strict glycemic control in diabetes, effective disease management for lupus or other autoimmune conditions can prevent or delay the onset of secondary nephrotic syndrome.
  • Avoidance of Nephrotoxic Agents: Judicious use of NSAIDs, gold salts, etc., especially in predisposed individuals.
• Secondary (Early Detection and Intervention):
  • Screening: Regular urinalysis in individuals at risk (e.g., diabetics, lupus patients) to detect proteinuria early.
  • Early Diagnosis and Biopsy: Prompt diagnosis of nephrotic syndrome and renal biopsy to identify the specific etiology allows for timely and targeted immunosuppressive therapy, potentially preventing irreversible kidney damage.
  • Aggressive Management of Proteinuria: Early initiation of ACEi/ARBs to reduce proteinuria and protect kidney function.
• Tertiary (Preventing Complications):
  • Prophylactic Anticoagulation: For high-risk patients (albumin <2.0-2.5 g/dL).
  • Aggressive Lipid Management: Statins to reduce cardiovascular risk.
  • Vaccinations: Pneumococcal, influenza, hepatitis B to reduce infection risk.
  • Dietary Sodium Restriction: To manage edema.
  • Blood Pressure Control: To prevent CKD progression and cardiovascular events.
  • Patient Education: Regarding medication adherence, signs of complications, and when to seek urgent medical attention.

Special Populations

• Pediatric:
  • Most Common Cause: Minimal Change Disease (MCD) (80-90% of cases).
  • Clinical Presentation: Often present with periorbital edema and anasarca, usually without hypertension or hematuria.
  • Treatment: Steroids are first-line. Most are steroid-responsive. Steroid-sparing agents (Cyclosporine, Tacrolimus, MMF, Rituximab) are used for steroid-dependent or frequently relapsing cases.
  • Complications: Higher risk of infections (peritonitis, cellulitis), hypovolemic crisis. Growth retardation and bone mineral density issues are long-term concerns with chronic steroid use.
  • Biopsy: Typically reserved for steroid-resistant cases, atypical features (hypertension, gross hematuria, low complement), or very young children (<1 year old).
• Geriatric:
  • Causes: Secondary causes (diabetic nephropathy, amyloidosis, malignancy-associated) and Membranous Nephropathy are more prevalent.
  • Comorbidities: Often have multiple comorbidities (cardiovascular disease, diabetes, hypertension) influencing management.
  • Drug Toxicity: Increased susceptibility to adverse effects of immunosuppressants and diuretics. Lower initial doses and careful titration are required.
  • Prognosis: Worse prognosis due to comorbidities and less aggressive treatment often tolerated.
• Pregnancy:
  • Diagnosis: Challenging due to physiological proteinuria and edema in pregnancy.
  • Risks: Increased risk of pre-eclampsia, preterm labor, maternal VTE. Nephrotic syndrome can worsen pre-eclampsia symptoms.
  • Management: Immunosuppression choices are limited (e.g., corticosteroids generally safe, MMF contraindicated). Close monitoring of proteinuria, blood pressure, and renal function is crucial. Therapeutic anticoagulation may be indicated.
• Comorbidities:
  • Diabetes Mellitus: Diabetic nephropathy is a leading cause. Management focuses on strict glycemic control, BP control, and RAAS blockade. SGLT2 inhibitors are now recommended for renoprotection.
  • Systemic Lupus Erythematosus (SLE): Lupus nephritis is a common manifestation. Treatment is highly specific to the lupus nephritis class and often involves corticosteroids and MMF or cyclophosphamide.
  • Heart Failure: Edema management is complicated; careful balance of diuretics is needed.
  • Malignancy: Paraneoplastic nephrotic syndrome requires treatment of the underlying cancer.
  • Chronic Liver Disease: Co-existing hypoalbuminemia and edema from liver failure can confound diagnosis and management.

Clinical Pearls

• Diagnostic:
  • "Foamy Urine + Edema" = Think Nephrotic Syndrome: This combination is the classic presentation.
  • 24-hour urine vs. UPCR: While 24-hour urine is gold standard, UPCR is practical and often sufficient for screening and monitoring.
  • Renal Biopsy is Key in Adults: Do not treat empirically in adults without a biopsy, unless there's a clear secondary cause (e.g., long-standing diabetic nephropathy with retinopathy) and no atypical features.
  • Search for Secondary Causes: Always perform a thorough workup for systemic diseases, infections, and drug exposures.
  • PLA2R: In adults with suspected primary MN, testing for anti-PLA2R antibodies can confirm diagnosis without a biopsy in specific clinical settings, and helps guide treatment and prognosis.
• Treatment:
  • Diuretics in Hypoalbuminemia: Remember that high doses of loop diuretics are often needed due to reduced delivery to the tubule. Consider combination therapy (e.g., Metolazone + Furosemide).
  • Albumin Infusion: Use judiciously. It's not a long-term solution for hypoalbuminemia. Best used for acute fluid mobilization with diuretics or for severe intravascular depletion.
  • RAAS Blockade is Cornerstone: ACEi/ARBs are crucial for proteinuria reduction and renoprotection, irrespective of blood pressure.
  • Statins for All: Due to high CV risk, nearly all nephrotic patients should be on statins.
  • Anticoagulation Threshold: Consider prophylactic anticoagulation for albumin <2.0-2.5 g/dL, especially with other risk factors.
  • Vaccinations: Crucial due to increased infection risk and immunosuppression.
• Pitfalls:
  • Treating Edema Aggressively Without Etiology: Symptom control is important, but definitive treatment for the underlying cause is paramount.
  • Underestimating Thrombotic Risk: Nephrotic syndrome is a hypercoagulable state; VTE can be deadly.
  • Overlooking Secondary Causes: Missing an underlying systemic disease can lead to inappropriate treatment and poorer outcomes.
  • Abrupt Cessation of Steroids: Risk of adrenal crisis. Always taper slowly.
  • Ignoring Cardiovascular Risk: Hyperlipidemia needs aggressive management.

Recent Updates

• Guidelines:
  • KDIGO (Kidney Disease: Improving Global Outcomes) Guidelines: Latest updates for Glomerular Diseases (e.g., 2021 update on Membranous Nephropathy) provide comprehensive, evidence-based recommendations for diagnosis and management of specific types of nephrotic syndrome.
  • SGLT2 Inhibitors: While primarily for diabetic kidney disease, recent guidelines and evidence (e.g., DAPA-CKD, EMPA-KIDNEY trials) suggest that SGLT2 inhibitors (e.g., Dapagliflozin, Empagliflozin) significantly reduce proteinuria and slow CKD progression in non-diabetic CKD patients, including those with primary glomerular diseases, making them a potential adjunctive therapy in nephrotic syndrome management.
• Evidence:
  • Rituximab in Membranous Nephropathy: Stronger evidence supports rituximab as a first-line alternative to cyclophosphamide-based regimens in high-risk MN, particularly for patients with anti-PLA2R positive disease.
  • Novel Therapies for FSGS: Emerging therapies for FSGS, including non-immunosuppressive agents targeting specific pathways (e.g., APOL1-related therapies) and more targeted immunomodulators, are under investigation.
  • APOL1 Genetic Testing: Increasingly recognized for its role in identifying individuals at higher risk for FSGS and more rapid progression to ESRD, particularly in individuals of African descent.
• Controversies:
  • Role of Routine Prophylactic Anticoagulation: While high-risk patients warrant it, the exact threshold and duration for prophylactic anticoagulation remain debated, balancing bleeding risk vs. thrombotic risk.
  • Biopsy in All Adults: While generally recommended, the increasing use of non-invasive diagnostics (e.g., anti-PLA2R antibodies for MN) prompts discussions on when biopsy can be safely deferred.
  • Optimal Duration of Immunosuppression: For many forms of nephrotic syndrome, the optimal duration of immunosuppressive therapy, especially calcineurin inhibitors, is still an area of active research to minimize side effects while preventing relapse.

Key References

• Guidelines:
  • KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases: Comprehensive, regularly updated guidelines covering various glomerular diseases, including MCD, FSGS, and MN. Available at kdigo.org.
  • American Society of Nephrology (ASN) Glomerular Disease Guidelines: Often align with or provide specific insights complementing KDIGO.
• Studies:
  • NEPTUNE Study: (Nephrotic Syndrome Study Network) - An observational cohort study and biorepository that aims to discover causes, progression, and treatment targets for primary glomerular diseases. Ongoing.
  • DAPA-CKD Trial (Dapagliflozin in Patients with Chronic Kidney Disease): Landmark trial demonstrating cardiovascular and renal benefits of SGLT2 inhibitors in patients with CKD, including those with glomerular diseases.
  • EMPA-KIDNEY Trial (Empagliflozin in Patients with Chronic Kidney Disease): Further solidified the renoprotective effects of SGLT2 inhibitors across a broad spectrum of CKD, including non-diabetic causes.
  • GEMRITUX Study (Membranous Nephropathy): Randomized controlled trial providing evidence for rituximab as an effective treatment for Membranous Nephropathy.
• Reviews:
  • UpToDate: Comprehensive, evidence-based clinical topic reviews covering all aspects of nephrotic syndrome.
  • Journal of the American Society of Nephrology (JASN) and Kidney International: Leading nephrology journals publishing original research and review articles.
  • Clinical Journal of the American Society of Nephrology (CJASN): Focuses on clinical aspects of nephrology.